Journal
CELL REPORTS
Volume 37, Issue 3, Pages -Publisher
CELL PRESS
DOI: 10.1016/j.celrep.2021.109839
Keywords
-
Categories
Funding
- Translational Research Institute of Space Health through NASA [T-0404]
- KBR, Inc.
- NASA High-End Computing (HEC) Program through the NASA Advanced Supercomputing (NAS) Division at Ames Research Center
- DOD [W81XWH-21-1-0128]
- NIGMS [P20 GM1009005]
- Individual National Research Service [F32-AI147587]
- NIH/NHBLI [K08 HL143271, NIH/NHLBI R03 HL155249]
- NIH/NCI [U54 CA260543, NSF 1956233]
- Biotechnology and Biological Sciences Research Council [BB/K004131/1, BB/F00964X/1, BB/M025047/1]
- Consejo Nacional de Ciencia y Tecnologia Paraguay (CONACyT) [14-INV-088andPINV15-315, 1660648]
- NSF IOS [1546858]
- CONACYT [PINV20-337]
- Fundacao Getulio Vargas
- National Center for Advancing Translational Sciences (NCATS)
- NIH [UL1TR002489, 2KR1272005, 550KR242003]
- Fundo de Apoio ao Ensino, Pesquisa e Extensao (FAEPEX) [2274/20]
- Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior-Brazil (CAPES) [001, A549 SARS-CoV-2]
- Division Of Integrative Organismal Systems
- Direct For Biological Sciences [1546858] Funding Source: National Science Foundation
Ask authors/readers for more resources
The research demonstrates that miR-2392 is associated with SARS-CoV-2 infection, with potential for use in COVID-19 detection and as a target for antiviral therapy. Targeting miR-2392 can significantly reduce SARS-CoV-2 viability, indicating a potential treatment for COVID-19.
MicroRNAs (miRNAs) are small non-coding RNAs involved in post-transcriptional gene regulation that have a major impact on many diseases and provide an exciting avenue toward antiviral therapeutics. From patient transcriptomic data, we determined that a circulatingmiRNA, miR-2392, is directly involved with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) machinery during host infection. Specifically, we show that miR-2392 is key in driving downstream suppression of mitochondrial gene expression, increasing inflammation, glycolysis, and hypoxia, as well as promoting many symptoms associated with coronavirus disease 2019 (COVID-19) infection. We demonstrate that miR-2392 is present in the blood and urine of patients positive for COVID-19 but is not present in patients negative for COVID-19. These findings indicate the potential for developing aminimally invasive COVID-19 detectionmethod. Lastly, using in vitro human and in vivo hamster models, we design a miRNA-based antiviral therapeutic that targets miR-2392, significantly reduces SARS-CoV-2 viability in hamsters, and may potentially inhibit a COVID-19 disease state in humans.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available